Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer

[1]  E. Iorns,et al.  Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer , 2018, PeerJ.

[2]  H. Lee,et al.  A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance , 2017, Scientific Reports.

[3]  Ming-Fong Lin,et al.  Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials , 2015, Therapeutic advances in urology.

[4]  Jun Luo,et al.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. , 2015, JAMA oncology.

[5]  D. Tindall,et al.  Are androgen receptor variants a substitute for the full-length receptor? , 2015, Nature Reviews Urology.

[6]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[7]  R. Ferraldeschi,et al.  Evolution of androgen receptor targeted therapy for advanced prostate cancer , 2014, Nature Reviews Clinical Oncology.

[8]  E. Wiemer,et al.  Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. , 2013, European journal of cancer.

[9]  Jun Luo,et al.  Decoding the androgen receptor splice variants , 2013, Translational andrology and urology.

[10]  H. Scher,et al.  A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer , 2013, Cancer Chemotherapy and Pharmacology.

[11]  W. Oh,et al.  Targeting the androgen receptor signalling axis in castration‐resistant prostate cancer (CRPC) , 2012, BJU international.

[12]  P. Albers,et al.  Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. , 2012, Urologic oncology.

[13]  S. Jang,et al.  A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL , 2012, Investigational New Drugs.

[14]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[15]  A. Gao,et al.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives , 2012, World Journal of Urology.

[16]  B. Mellado,et al.  Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer , 2011, Molecular Cancer Therapeutics.

[17]  D. Tindall,et al.  Alternatively spliced androgen receptor variants. , 2011, Endocrine-related cancer.

[18]  N. Bander,et al.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. , 2011, Cancer research.

[19]  K. Fizazi,et al.  Targeting Continued Androgen Receptor Signaling in Prostate Cancer , 2011, Clinical Cancer Research.

[20]  C. Bevan,et al.  Androgen Receptor Signalling in Prostate Cancer: The Functional Consequences of Acetylation , 2010, Journal of Biomedicine and Biotechnology.

[21]  Dong Eun Kim,et al.  Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. , 2010, The Journal of urology.

[22]  H. Scher,et al.  A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer , 2010, Cancer Chemotherapy and Pharmacology.

[23]  David C. Smith,et al.  Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862) , 2009, Cancer.

[24]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  N. Bander,et al.  Docetaxel down‐regulates the expression of androgen receptor and prostate‐specific antigen but not prostate‐specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy , 2009, The Prostate.

[26]  K. Chin,et al.  Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression , 2009, Clinical Cancer Research.

[27]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[28]  L. Borsu,et al.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. , 2009, Cancer research.

[29]  Yong J. Lee,et al.  Pretreatment of docetaxel enhances TRAIL‐mediated apoptosis in prostate cancer cells , 2008, Journal of cellular biochemistry.

[30]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[31]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[32]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[35]  A. Riegel,et al.  Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter. , 1999, Experimental cell research.

[36]  S. Dehm,et al.  Constitutive activity of the androgen receptor. , 2014, Advances in pharmacology.

[37]  I. Tannock,et al.  Drug resistance in metastatic castration-resistant prostate cancer , 2011, Nature Reviews Clinical Oncology.

[38]  D. Qian,et al.  Cancer esearch apeutics , Targets , and Chemical Biology ulin-Targeting Chemotherapy Impairs Androgen R eptor Activity in Prostate Cancer , 2010 .

[39]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[40]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[41]  D. Bissett,et al.  Taxol and taxotere--current status and future prospects. , 1993, European journal of cancer.

[42]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.